Search

Sipavibart

[L53418] Sipavibart gained its first global approval in Japan in December 2024.[A274088] It was later approved in Europe in January 2025 and in Canada in March 2025. … [A274088] Sipavibart is approved for the pre-exposure prophylaxis treatment of COVID-19 in immunocompromised patients.[L53418]

Bromocriptine

In 1995, the FDA withdrew the approval of bromocriptine mesylate for the prevention of physiological lactation after finding that bromocriptine was not shown to be safe for use. … Bromocriptine has been associated with pulmonary fibrosis, and can also cause sustained suppression of somatotropin (growth hormone) secretion in some patients with acromegaly.

Tea tree oil

Tea tree oil is an essential oil derived mainly from the Australian native plant _Melaleuca alternifolia_ via steam distillation of the of the leaves and terminal branches [A32439]. … It has been a popular ingredient in a variety of household and cosmetic products due to its antiseptic, anti-inflammatory, broad-spectrum antimicrobial and antioxidant properties [A32438].

Potassium cation

The balance between potassium and sodium is maintained by ion pumps in the cell membrane. … Potassium is also an essential mineral needed to regulate water balance, blood pressure and levels of acidity.

Dicyclomine

[L7982] Dicyclomine was granted FDA approval on 11 May 1950.[L7967] … [A6556,A182555,A234659,L7967] Though it is commonly prescribed, its recommendation may have been based on a small amount of evidence and so its prescription is becoming less favourable.

Romidepsin

Romidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy

Methoxyflurane

An inhalation anesthetic. Currently, methoxyflurane is rarely used for surgical, obstetric, or dental anesthesia. … (From AMA Drug Evaluations Annual, 1994, p180) In the US, methoxyflurane is one of the products that have been withdrawn or removed from the market for reasons of safety or effectiveness.[L43942]

Brentuximab vedotin

Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). … It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large-cell lymphoma. Brentuximab vedotin was initially approved in 2011.

Calcium alginate

Givinostat

[L50316,A263446] Givinostat was granted FDA approval in March 2024 for the treatment of patients ≥6 years of age with Duchenne muscular dystrophy (DMD). … In the context of muscular dystrophy, inhibitors of HDAC appear to exert their therapeutic effects by targeting pathogenic processes that cause inflammation and muscle loss.